What is stem cell therapy, and how does it work?

No. We use adult mesenchymal stromal cells, most often from umbilical-cord tissue donated after healthy, full-term births. They are always donor cells; your own blood is used only for PRP. Embryonic stem cells are a different cell type with a different legal and ethical history; they are not used in any of our protocols.

For the indications the physician team treats, MSCs work primarily through paracrine signaling: they release cytokines, growth factors, and exosomes that instruct your existing cells to repair and rebalance. Thinking of them as "replacement cells" is the most common misunderstanding the team corrects during intake calls. The goal is to change the conditions so the body's own repair capacity can function again.

The cells are the trigger. The signaling cascade they initiate (reduced inflammation, improved biomarkers, symptom relief) continues well beyond the cells themselves. Duration varies by indication and individual response; the physician team discusses what's realistic for your case during review. The mental model is "the cells initiate a cascade," not "the cells stay forever."

Exosomes are the signaling packets that MSCs secrete. A cell-free exosome preparation can be an option for patients who cannot tolerate a cellular infusion or for specific adjunct uses. The regulatory and manufacturing requirements are different, and the evidence base is smaller. We use exosomes selectively, not as a primary therapy for most indications.

The most common events are transient: low-grade fever, headache, fatigue, occasional mild flushing during infusion. Serious adverse events in the peer-reviewed MSC literature run at rates comparable to placebo (see reference 13 in the research list). Unusual but possible events include allergic reaction to preservatives, and, very rarely, transient pulmonary symptoms when IV cells lodge briefly in lung capillaries. We screen for risk factors in advance.

This is the question we get most often and the one worth taking seriously. There is no credible evidence that the MSC preparations we use are tumorigenic in humans. The concern is biologically reasonable. MSCs can support cell growth in certain contexts, which is why we screen carefully for active malignancy and why every batch passes six release tests (sterility, identity, viability, potency, endotoxin, mycoplasma) before it is used. We will not infuse a patient with active cancer.

Depending on the condition and its stage, an autoimmune diagnosis can be either an indication (in quiet or early-stage disease) or a contraindication (in active flare). We review records and, when needed, consult with your existing specialist before making a recommendation. Some autoimmune patients we accept; some we decline.

Depends on indication. A joint or spine protocol is one session, and whether a second treatment makes sense is decided at your follow-up reviews. For an IV, the 6-month review decides what happens next. Neurologic programs are individualized, and repeats are decided at review. An unlimited-dose model is a red flag; our protocols have a defined endpoint.

It varies. After an IV, some patients report more energy in the first 2 weeks, and the response peaks around 12 to 16 weeks. In a joint, the first change comes between weeks 4 and 12, and improvement can keep building through the first year. Some patients notice no change at all. We set expectations on the first call.

Yes. Most patients are home the same day, joint and spine patients included, after the attending physician signs your discharge. A Celva driver takes you back across the border. An overnight happens only when your intake says so; you are told before you travel, not on arrival.

U.S. insurance does not cover cell therapy performed in Mexico, and most U.S. policies do not cover cell therapy performed in the U.S. either, because the products are not FDA-approved for the indications involved. Treatment is generally self-pay and out-of-pocket. HSA and FSA eligibility depends on your plan; verify with your plan administrator. We do not advertise insurance coverage we cannot deliver.

Most common reasons: active malignancy; a diagnosis where cell therapy genuinely can't help and we won't pretend otherwise; a complete rotator cuff tear or similar structural problem that needs surgical repair; unrealistic expectations we cannot correct; or an incomplete medical workup that needs to happen before we make a recommendation. Bone-on-bone joints are not an automatic decline; we'll still consider treating you if you want to delay joint replacement, with a frank conversation about the lower expected response.

Some patients show little or no change. We do not repeat protocols on non-responders as a default, that is selling, not medicine. We review the case, consider whether a different route or adjunct is appropriate, or whether cell therapy was not the right tool. Honesty here is part of the service.

It can. For early-to-moderate joint disease, some patients delay replacement. For late-stage bone-on-bone disease, the expected response is lower; we'll still consider treating you if you want to delay surgery, with realistic expectations. For structural problems (torn ligament, complete tendon rupture), cell therapy is not the primary treatment. The honest answer depends on imaging and clinical exam, which is why we ask for them.

Read it with the same skepticism you'd bring to any medical-marketing page, including ours. Then compare it with the references linked above, with ClinicalTrials.gov, and with your own doctor's view. If you find something on this page that is wrong or misleading, email [email protected] and we will correct it. That offer is standing.